OncoSil Medical Limited

OSL

AU000000OSL3

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 02:10:52 2024-06-03 am EDT			5-day change	1st Jan Change
0.005 ^AUD	0.00%		-9.09%	-44.44%

03:08am	Oncosil Medical Treats 200th Pancreatic Cancer Patient with Proprietary Device	MT
May. 23	Oncosil Medical Enters Distribution Agreement with Abdulla Fouad Group for Saudi Arabia	MT

OncoSil Medical Limited Appoints Ricky Sharma as Non-Executive Director, Effective 1 November 2021

October 11, 2021 at 07:43 pm EDT

The Board of OncoSil Medical Ltd. announced the appointment of Professor Ricky Sharma to the company board as a non-executive director effective 1 November 2021. Professor Sharma is an international authority on the translation of radiobiology from the laboratory to the clinic and on the multi-modality treatment of cancer with precision radiotherapy. He is currently Vice President Clinical Affairs at Varian.

Latest news about OncoSil Medical Limited

Oncosil Medical Treats 200th Pancreatic Cancer Patient with Proprietary Device	09:08pm	MT
Oncosil Medical Enters Distribution Agreement with Abdulla Fouad Group for Saudi Arabia	May. 22	MT
OncoSil Medical Raises AU$5.3 Million under Entitlement Offer	May. 01	MT
OncoSil Medical Treats Two More Patients in Netherlands in Pancreatic Cancer Trial	Apr. 17	MT
OncoSil Medical Treats First Commercial Patient in Turkey with Implantable Pancreatic Cancer Device	Apr. 15	MT
OncoSil Medical Treats First UK Patient for Pancreatic Cancer Study	Apr. 11	MT
OncoSil Medical Obtains Device Reimbursement Approval in UK	Apr. 08	MT
First Austria-Based Patients Treated Using OncoSil Pancreatic Cancer Device	Apr. 04	MT
Oncosil Medical Issues Non-Renounceable Entitlement Offer Prospectus	Mar. 24	MT
Oncosil Medical to Raise Over AU$7 Million via Placement, Entitlement Offer	Mar. 19	MT
OncoSil Medical Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 28	CI
Australian Shares End Eight-Day Winning Streak as Early US Fed Rate Cut Hopes Fade	Feb. 01	MT
OncoSil Device Included in German Funding Program Negotiations; Shares Jump 14%	Jan. 31	MT
OncoSil Strikes Exclusive Distribution Deal For Turkish Market; Shares Jump 14%	Jan. 31	MT
OncoSil Medical Receives AU$1.1 Million R&D Tax Rebate	Dec. 15	MT
First Patient Treated in OncoSil Medical's Pancreatic Cancer Drug Trial	Nov. 28	MT
Oncosil Medical Limited Elects Gabrielle Liberatore as Director	Nov. 28	CI
Australian Shares Rise on Expectations of Easing October CPI	Nov. 24	MT
OncoSil Medical Secures Insurer Clearance for Pancreatic Cancer Device in Israel	Nov. 23	MT
OncoSil Medical Limited Announces Retirement of Brian Leedman from the Board	23-09-18	CI
OncoSil Medical Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-31	CI
Oncosil Medical Limited Announces Change of Principal Place of Business	23-08-16	CI
OncoSil Medical Limited Appoints Doug Cubbin as Director	23-08-09	CI
Oncosil Medical Appoints Incoming Chair	23-08-07	MT
OncoSil Appoints Gabriel Liberatore to the Board	23-07-14	CI

Chart OncoSil Medical Limited

Duration

Period

More charts

Company Profile

OncoSil Medical Ltd is an Australia-based medical device company focused on localized treatments for patients with unresectable locally advanced pancreatic cancer (LAPC). The Company is focused on the development and commercialization of its lead product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The Company has developed a cancer treatment device, the OncoSil brachytherapy device, which is a critical component of a brachytherapy treatment for locally advanced unresectable pancreatic cancer. The OncoSil device delivers a targeted intratumoral placement of Phosphorous-32 (32P) in the treatment of locally advanced unresectable pancreatic cancer. The OncoSil device has received a device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy.

Sector

Pharmaceuticals

Calendar

2024-08-21 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ONCOSIL MEDICAL LIMITED	-44.44%	11.06M
ELI LILLY AND COMPANY	+40.73%	739B
NOVO NORDISK A/S	+31.66%	598B
JOHNSON & JOHNSON	-6.30%	353B
MERCK & CO., INC.	+15.15%	318B
ABBVIE INC.	+4.05%	285B
ASTRAZENECA PLC	+15.41%	240B
NOVARTIS AG	+9.45%	210B
ROCHE HOLDING AG	-5.48%	206B
AMGEN INC.	+6.17%	164B

Other Pharmaceuticals